News ArticleAlkem Laboratories Incorporates 51% Owned Joint Venture 'Alkem Pharma Company' in Saudi Arabia
The new subsidiary has a capital of 7,500,000 SAR with Alkem subscribing 38,250 shares through a cash consideration of 3,825,000 SAR, targeting pharmaceutical and nutraceutical markets in the Kingdom of Saudi Arabia.
Alkem Laboratories Limited has established a new subsidiary in Saudi Arabia named 'Alkem Pharma Company' with a capital of 7,500,000 SAR, acquiring a 51% stake through a cash investment of 3,825,000 SAR. This joint venture aims to manufacture, import, market, and distribute pharmaceutical and nutraceutical products, marking a strategic expansion into the Kingdom of Saudi Arabia's market.
Alkem Laboratories Limited
Acquisition / Amalgamation / Merger / Demerger
Alkem Laboratories Limited has formed a new subsidiary in Saudi Arabia called 'Alkem Pharma Company', a joint venture with Alkem holding 51% of shares through a cash investment of 3,825,000 SAR. The company aims to expand its pharmaceutical and nutraceutical business presence in the Kingdom of Saudi Arabia.
The subsidiary, incorporated as a limited liability company on 8th November 2026, has a capital of 7,500,000 SAR divided into 75,000 shares of 100 SAR each.
Alkem Laboratories holds a majority 51% stake, subscribing to 38,250 shares paid in cash.
This joint venture is focused on the manufacturing, importing, marketing, and distribution of pharmaceutical and nutraceutical products within Saudi Arabia.
The acquisition does not involve any related party transactions, and no promoters or group companies have an interest in this joint venture.
No governmental or regulatory approvals were required for this incorporation, and no indicative time period for completion applies as the entity was already incorporated on the stated date.
Highlights
- New subsidiary 'Alkem Pharma Company' incorporated in Saudi Arabia on 8th November 2026.
- Issued capital of the subsidiary is 7,500,000 SAR with 75,000 shares of 100 SAR each.
- Alkem Laboratories holds 51% ownership with 38,250 shares.
- Investment made through a cash consideration of 3,825,000 SAR.
- Subsidiary operates in pharmaceuticals and nutraceuticals sector.
- No related party involvement or promoter interest in this joint venture.
Key Data Snapshot
What happened
- Alkem Laboratories incorporated a subsidiary joint venture named 'Alkem Pharma Company' in the Kingdom of Saudi Arabia on 8th November 2026.
- The company acquired a 51% controlling stake through a cash investment in the joint venture.
Key details
- The subsidiary has an issued capital of 7,500,000 SAR divided into 75,000 shares of 100 SAR each.
- Alkem Laboratories subscribed to 38,250 shares by paying a cash amount of 3,825,000 SAR.
- The joint venture is established as a limited liability company to operate in pharmaceuticals and nutraceuticals.
- No related party transactions or promoter interests are involved in this acquisition.
Strategic context
- The joint venture aims to expand Alkem Laboratories' business operations and market reach into the Kingdom of Saudi Arabia.
- The entity will handle manufacturing, import, marketing, and distribution of pharmaceutical and nutraceutical products locally.
Regulatory and governance context
- No government or regulatory approvals were required for the incorporation of this subsidiary.
- No indicative time period for completion was applicable given the incorporation date provided.
Highlights
- New subsidiary 'Alkem Pharma Company' incorporated in Saudi Arabia on 8th November 2026.
- Issued capital of the subsidiary is 7,500,000 SAR with 75,000 shares of 100 SAR each.
- Alkem Laboratories holds 51% ownership with 38,250 shares.
- Investment made through a cash consideration of 3,825,000 SAR.
- Subsidiary operates in pharmaceuticals and nutraceuticals sector.
- No related party involvement or promoter interest in this joint venture.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30
- SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026
No related party transaction
None
More News on Acquisition / Amalgamation / Merger / Demerger
View allLatest corporate announcements and market updates in Acquisition / Amalgamation / Merger / Demerger.
Tata Motors Subsidiary Acquires 96.25% of Iveco Group Through Tender Offer Finalization
Tata Motors Limited's wholly owned subsidiary, TML CV Holdings B.V., has successfully increased its stake in Iveco Group N.V. to approximately 96.25% of the common share capital following a voluntary totalitarian tender offer and reopening of terms.
Read Full Story
Aequs Limited Obtains Bengaluru Regional Directorate Approval for Subsidiaries’ Amalgamation Scheme Effective April 2026
Aequs Limited has received official sanction from the Bengaluru Regional Directorate for the Scheme of Amalgamation of its three wholly owned subsidiaries, with effect from April 1, 2026, after a successful appeal with the Ministry of Corporate Affairs correcting a prior rejection.
Read Full Story
Nirma Limited Sells 36.8 lakh Shares, Cuts Stake in Alivus Life Sciences to 71.74%
Nirma Limited, a promoter of Alivus Life Sciences Limited, has sold 36,80,000 equity shares in an open market sale on 6th November 2026, decreasing its shareholding to 71.74% from 74.73%.
Read Full Story
